0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Atossa Genetics Inc

Healthcare US ATOS

1.52USD
0.02(1.33%)

Last update at 2024-04-25T20:00:00Z

Day Range

1.451.57
LowHigh

52 Week Range

0.501.39
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -26.96000M -20.60600M -17.82795M -17.23978M -11.40493M
Minority interest - - - - -
Net income -26.22900M -20.60600M -21.09931M -17.23978M -11.40493M
Selling general administrative 12.61M 11.31M 8.00M 10.62M 7.22M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.00800M 0.02M 0.05M 0.05M 0.04M
Ebit -27.69900M -20.52100M -14.60739M -17.26543M -11.43423M
Ebitda -27.69100M -20.49800M -11.28951M -17.21264M -11.39004M
Depreciation and amortization 0.00800M 0.02M 3.32M 0.05M 0.04M
Non operating income net other 0.73M -0.08500M -2.28177M 0.03M 0.03M
Operating income -27.69100M -20.52100M -14.60739M -17.26543M -11.43423M
Other operating expenses 27.69M 20.52M 14.61M 17.27M 11.43M
Interest expense -0.00800M 0.09M 0.94M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -
Interest income 0.88M - - - -
Net interest income 0.88M - -0.93879M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.73100M 0.09M 3.27M -0.02565M -0.02930M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 27.69M 20.52M 14.61M 17.27M 11.43M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.73M -0.08500M -3.22056M 0.03M 0.03M
Discontinued operations - - - - -
Net income from continuing ops -26.96000M -20.60600M -17.82795M -17.23978M -11.40493M
Net income applicable to common shares -26.96000M -20.60600M -22.33075M -17.23978M -22.88424M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 123.53M 141.26M 42.84M 14.49M 11.72M
Intangible assets - - 0.01M 0.07M 0.10M
Earning assets - - - - -
Other current assets 2.42M 1.19M 0.66M 0.03M 0.03M
Total liab 5.57M 3.13M 15.67M 1.33M 2.92M
Total stockholder equity 117.96M 138.14M 27.17M 13.16M 8.81M
Deferred long term liab - - - - -
Other current liab 2.60M 1.41M 13.01M 0.01M 2.56M
Common stock 22.79M 22.79M 8.56M 1.64M 1.05M
Capital stock 22.79M 22.79M 8.56M 1.64M 1.05M
Retained earnings -156.19400M -129.23400M -111.89899M -94.07104M -76.83126M
Other liab - - - - -
Good will - - - - -
Other assets 0.64M 0.00200M 0.06M 0.00035M 0.02M
Cash 110.89M 136.38M 39.55M 12.58M 10.38M
Cash and equivalents - - - - -
Total current liabilities 5.57M 3.13M 15.67M 1.32M 2.92M
Current deferred revenue - - 1.06M 0.98M -
Net debt -110.89000M -136.37700M -39.53562M -12.53066M -10.38049M
Short term debt - - 0.02M 0.04M -
Short long term debt - - - - -
Short long term debt total - - 0.02M 0.05M -
Other stockholder equity 250.78M 244.58M 130.51M 105.58M 84.58M
Property plant equipment - 0.02M 0.04M 0.03M 0.05M
Total current assets 118.20M 141.24M 42.77M 14.32M 11.55M
Long term investments 4.70M - - - -
Net tangible assets 117.96M 137.55M 26.53M 13.16M 8.71M
Short term investments - - - - -
Net receivables 0.74M 1.07M 0.63M 0.74M 0.52M
Long term debt - - - - -
Inventory 4.14M 2.60M 1.92M 0.97M 0.62M
Accounts payable 2.96M 1.72M 1.59M 0.29M 0.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.58200M - -0.15100M -
Additional paid in capital - - - - -
Common stock total equity 22.79M 22.79M 13.00M 1.64M 1.05M
Preferred stock total equity - - 0.00000M 0.00000M 0.00000M
Retained earnings total equity -156.19400M -129.23400M -111.89899M -94.07104M -76.83126M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.64M 0.00200M 0.02M 0.02M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 5.33M 0.02M 0.07M 0.17M 0.17M
Capital lease obligations - 0.00000M 0.02M 0.05M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.72700M -0.00900M -0.00937M -0.00762M -0.11091M
Change to liabilities 2.44M 0.13M 1.30M -0.22204M 0.28M
Total cashflows from investing activities -4.72700M -0.00900M -0.00937M -0.00762M -0.11091M
Net borrowings - - - - -
Total cash from financing activities 0.00000M 113.30M 38.55M 11.34M 12.29M
Change to operating activities -1.84700M -1.28400M -1.40679M -0.73114M -0.08283M
Net income -26.96000M -20.60600M -17.82795M -17.23978M -11.40493M
Change in cash -25.48700M 96.82M 26.97M 2.20M 3.22M
Begin period cash flow 136.49M 39.66M 12.69M 10.49M 7.27M
End period cash flow 111.00M 136.49M 39.66M 12.69M 10.49M
Total cash from operating activities -20.76000M -16.47200M -11.57028M -9.12844M -8.96162M
Issuance of capital stock 0.00000M 69.67M 38.57M 0.00000M 12.29M
Depreciation 0.00800M 0.02M 0.05M 0.05M 0.04M
Other cashflows from investing activities -4.70000M - - - -
Dividends paid - - -4.50280M - -
Change to inventory - - - - -
Change to account receivables - - 0.10M - -
Sale purchase of stock - 44.21M 9.61M 11.34M 12.29M
Other cashflows from financing activities -4.72700M 43.64M 9.44M 11.34M -0.11091M
Change to netincome 6.79M 5.27M 6.32M 7.11M 1.05M
Capital expenditures 0.03M 0.00900M 0.00937M 0.00762M 0.11M
Change receivables - - - - -
Cash flows other operating -3.04100M -1.63200M -0.53958M 1.17M 1.07M
Exchange rate changes - - - - -
Cash and cash equivalents changes -25.48700M 96.82M 26.97M 2.20M 3.22M
Change in working capital -0.59900M -1.15600M -0.11135M -0.79130M -0.06441M
Stock based compensation 6.79M 5.27M 3.02M 8.84M 2.46M
Other non cash items 0.00300M 26.96M 0.94M 0.00581M -2.02571M
Free cash flow -20.78700M -16.48100M -11.57965M -9.13607M -9.07253M

Fundamentals

  • Previous Close 1.50
  • Market Cap105.63M
  • Volume852744
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-30.48500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.24

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ATOS
Atossa Genetics Inc		 0.02 1.33% 1.52 - - - 0.91 0.17
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atossa Genetics Inc

107 Spring Street, Seattle, WA, United States, 98104

Key Executives

Name Title Year Born
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & Pres 1951
Mr. Kyle Guse CPA, Esq., CPA CFO, Gen. Counsel & Sec. 1964
Ms. Heather Rees VP of Fin. & Accounting NA
Ms. Delly Behen P.H.R. VP of Admin. & HR NA
Ms. Janet Rose Rea MSPH, RAC Sr. VP of Regulatory, Quality & Clinical Affairs NA
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).